Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy
Condition: Muscular Atrophy, Spinal
MeSH terms: Muscular Atrophy; Muscular Atrophy, Spinal; Atrophy
Intervention: Risdiplam
Intervention description: Risdiplam will be administered orally.
Intervention MeSH terms: Risdiplam
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Non-Randomized
Intervention model: Sequential Assignment
Masking: None (Open Label)
Enrollment: 62.0
Sex: All
Minimum age: 1 Month
Maximum age: 7 Months
Healthy volunteers: No

Summary:

      Open-label, multi-center clinical study is to assess the safety, tolerability,
      pharmacokinetic (PK), pharmacodynamics (PD), and efficacy of Risdiplam (RO7034067) in infants
      with Type 1 spinal muscular atrophy (SMA). The study consists of two parts, an exploratory
      dose finding part (Part 1) and a confirmatory part (Part 2) which will investigate Risdiplam
      (RO7034067) for 24-months at the dose selected in Part 1.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Clinical history, signs or symptoms attributable to Type 1 SMA with onset after 28
             days but prior to the age of 3 months

          -  Gestational age of 37 to 42 weeks

          -  Confirmed diagnosis of 5q-autosomal recessive SMA

          -  Participants has two survival motor neuron 2 (SMN2) gene copies, as confirmed by
             central testing

          -  Body weight greater than or equal to (>=) third percentile for age, using appropriate
             country-specific guidelines

          -  Receiving adequate nutrition and hydration (with or without gastrostomy) at the time
             of screening, in the opinion of the Investigator

          -  Adequately recovered from any acute illness at the time of screening and considered
             well-enough to participate in the opinion of the Investigator

        Exclusion Criteria:

          -  Concomitant or previous participation in any investigational drug or device study
             within 90 days prior to screening or 5 half-lives, whichever is longer

          -  Concomitant or previous administration of SMN2-targeting antisense oligonucleotide,
             SMN2 splicing modifier or gene therapy study

          -  Any history of cell therapy

          -  Hospitalization for pulmonary event within the last 2 months, or planned at the time
             of screening

          -  Presence of clinically relevant electrocardiogram (ECG) abnormalities before study
             drug administration

          -  Unstable gastrointestinal, renal, hepatic, endocrine or cardiovascular system diseases

          -  Participants requiring invasive ventilation or tracheostomy

          -  Participants requiring awake non-invasive ventilation or with awake hypoxemia
             (arterial oxygen saturation less than [<] 95 percent [%]) with or without ventilator
             support

          -  Participants with a history of respiratory failure or severe pneumonia, and have not
             fully recovered their pulmonary function at the time of screening

          -  Multiple or fixed contractures and/or hip subluxation or dislocation at birth

          -  Presence of non-SMA related concurrent syndromes or diseases

          -  Any major illness within one month before the screening examination or any febrile
             illness within one week prior to screening and up to first dose administration

          -  Any inhibitor of cytochrome P450 (CYP) 3A4 and/or any Organic Cation Transporter 2
             (OCT-2) and multidrug and toxin extrusion (MATE) substrates taken within 2 weeks
             and/or any inducer of CYP3A4 taken within 4 weeks (or within 5-times the elimination
             half-life, whichever is longer) prior to dosing or participants (and the mother, if
             breastfeeding the infant) taking any nutrients known to modulate CYP3A activity and
             any known flavin containing monooxygenase (FMO) 1 or FMO3 inhibitors or substrates

          -  Prior use (at any time in the participants lives) and/or anticipated need for
             quinolones (chloroquine and hydroxychloroquine), thioridazine, vigabatrin, retigabine,
             or any other drug known to cause retinal toxicity during the study. Infants exposed to
             chloroquine, hydroxycholoroquine, thioridazine, vigabatrin, retigabine or drugs with
             known retinal toxicity given to mothers during pregnancy (and lactation) should not be
             enrolled.

          -  Recent history (less than 6 months) of ophthalmic disease that would interfere with
             the conduct of the study as assessed by an ophthalmologist

          -  Therapeutic use, defined as use for 8 weeks or longer, of the following medications
             within 90 days prior to enrollment: riluzole, valproic acid, hydroxyurea, sodium
             phenylbutyrate, butyrate derivatives, creatine, carnitine, growth hormone, anabolic
             steroids, probenecid, agents anticipated to increase or decrease muscle strength,
             agents with known or presumed histone deacetylase (HDAC) inhibitory effect,
             medications known to or suspected of causing retinal toxicity (deferoxamine,
             topiramate, latanoprost, niacin, rosiglitazone, tamoxifen, canthaxanthine, sildenafil,
             and interferon) and medications with known phototoxicity liabilities (e.g., oral
             retinoids including over-the-counter [OTC] formulations, amiodarone, phenothiazines
             and use of minocycline)